Physician profile
Sofya A Kleyn
NPI 1972628865
$1,762.04
in general payments reported to CMS, 2019-2025
19 companies · $535 in 2025
The $535 reported for 2025 was more than what 80% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.56 · 2020: $30.28 · 2021: $224 · 2022: $111 · 2023: $94.41 · 2024: $748 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $400.82 | 2024-2025 | Apretude |
| Abbvie INC. | $255.42 | 2021-2024 | |
| Lilly USA, LLC | $166.69 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Amgen INC. | $145.75 | 2022-2024 | Tepezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.79 | 2025 | Caplyta |
| Abbott Laboratories | $104.33 | 2024-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $96.23 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $85.15 | 2020-2025 | Breztri, Airsupra |
| Biogen, INC. | $69.58 | 2021 | |
| Almatica Pharma LLC | $58.16 | 2025 | Loreev Xr |
| Lundbeck LLC | $42.85 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.12 | 2023 | Xifaxan, Trulance |
| Corium, LLC | $33.06 | 2023 | Adlarity |
| Novo Nordisk INC | $29.12 | 2025 | Rybelsus, Ozempic |
| Opko Pharmaceuticals, LLC | $28.69 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $26.41 | 2024 | |
| Scilex Pharmaceuticals INC. | $23.78 | 2024 | |
| Eisai INC. | $22.29 | 2024 | |
| Phadia US INC. | $15.80 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofya Kleyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.